The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 17, 2026 for Espee Therapeutics LLP

Ownership Changes View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹791.15

prior close

₹795.60

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%-0.9% vs market

Pharmaceuticals peers, median of 157sector+0.2%-0.2% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.1

15m

-0.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+1.0-0.9+0.2-0.2

Next day

+3.9+1.3+2.6+0.6+3.2

+2.5-0.2+2.7-0.4+2.9

+2.5-0.3+2.8-0.6+3.1

+0.3-0.2+0.5-0.3+0.6

-1.0-1.4+0.4-1.6+0.6

-1.3-1.0-0.3-0.6-0.7

15d

-6.5-6.3-0.2-4.2-2.3

-5.4-9.0+3.6-5.8+0.4

+12.9+3.5+9.4+1.4+11.4

+43.2+4.6+38.6+4.1+39.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Espee Therapeutics LLP, part of the promoter group of Senores Pharmaceuticals Ltd, has created a pledge on 4,00,000 equity shares (0.87% of total share capital) of the company in favour of Bajaj Finance Limited. The pledge was created on February 13, 2026, and the reason stated is to secure a loan taken by Renosen Pharmaceuticals Private Limited (a related entity within the promoter group), making this a third-party pledge. Espee Therapeutics LLP holds 4,95,000 shares (1.07% of share capital) in total, so the pledge covers about 80% of its own holding in Senores. The disclosure has been filed under Regulation 31(1) and 31(2) of SEBI's SAST Regulations.

Likely market impact

This is a relatively small pledge in terms of overall company share capital (under 1%), but it signals that a promoter group entity is using its Senores shares as collateral to raise funds for another group company. Investors should watch for any stress in Renosen Pharmaceuticals, as enforcement of this pledge by Bajaj Finance could lead to a change in shareholding of Senores Pharmaceuticals.